Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study in Healthy Men to Test if Different Formulations of BI 764198 With or Without Food Influence the Amount of BI 764198 in the Blood
Sponsor: Boehringer Ingelheim
Summary
BI 764198 is intended to be used in patients hospitalized for COVID-19 at risk of respiratory complications. The present trial will investigate the relative bioavailability of BI 764198 administered as capsules versus tablets in a first part, and the relative bioavailability and food effect of four oral formulations: the newly developed tablet formulation under fed and fasted conditions as well as suspension from capsules and suspension from tablets in a second part.
Official title: A Two-part Phase I Trial Investigating the Relative Bioavailability and Food Effect of Different Oral Formulations of BI 764198 in Healthy Subjects (an Open-label, Single-dose, Randomised, Crossover Study)
Key Details
Gender
MALE
Age Range
18 Years - 50 Years
Study Type
INTERVENTIONAL
Enrollment
28
Start Date
2021-01-15
Completion Date
2021-03-15
Last Updated
2026-07-06
Healthy Volunteers
Yes
Conditions
Interventions
BI 764198 - Formula A
BI 764198
BI 764198 - Formula B
BI 764198
BI 764198 - Formula C
BI 764198
BI 764198 - Formula D
BI 764198
Locations (1)
SGS Belgium NV Research Unit Stuivenberg
Antwerp, Belgium